{"id":"W2080237150","doi":"10.1111/bjd.13814","title":"Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Dosing; Randomized controlled trial; Interleukin 17; Internal medicine; Dermatology; Cytokine; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002489459,0.001013176,0.002189925,0.000371097,0.0003094282,0.0009158612,0.0005800198,0.001268268,0.007666382],"category_scores_gemma":[0.00193486,0.0004225588,0.00181764,0.0004417388,0.0007144943,0.0006861764,0.0002858996,0.001964638,0.0008008051],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003696955,"about_ca_system_score_gemma":0.0006156695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003719683,"about_ca_topic_score_gemma":0.001041421,"domain_scores_codex":[0.9990661,0.0005913934,0.00006059456,0.0001062915,0.0000827484,0.00009286793],"domain_scores_gemma":[0.9989454,0.0003766209,0.0003277543,0.00008249118,0.00006152774,0.0002062617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9549966,0.005578031,0.0007631062,0.001749353,0.001783691,0.00005238341,0.00005066741,0.0003886726,0.004203624,0.0001334805,0.001169363,0.029131],"study_design_scores_gemma":[0.9300565,0.06509881,0.002552932,0.00007653806,0.0006001297,0.00006343237,0.00001503852,0.0003157579,0.0004073781,0.0001271805,0.0006754241,0.00001092217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9712573,0.01690511,0.001037726,0.001102751,0.0005292005,0.00477196,0.001555037,0.0002465972,0.002594386],"genre_scores_gemma":[0.9814746,0.007017929,0.001872425,0.001236475,0.0004389134,0.00497259,0.0009308179,0.00003603941,0.002020208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007666382,"threshold_uncertainty_score":0.02564657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01857271942566301,"score_gpt":0.2995247510734746,"score_spread":0.2809520316478116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}